|
|
Volumn 13, Issue 2, 2002, Pages 86-87
|
|
Atazanavir demonstrates antiviral efficacy and a favorable lipid profile at 48 weeks.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CHOLESTEROL;
NELFINAVIR;
PROTEINASE INHIBITOR;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ARTICLE;
BLOOD;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
HUMAN;
RANDOMIZED CONTROLLED TRIAL;
ACQUIRED IMMUNODEFICIENCY SYNDROME;
CHOLESTEROL;
HIV PROTEASE INHIBITORS;
HUMANS;
NELFINAVIR;
RANDOMIZED CONTROLLED TRIALS;
|
|
EID: 0036515229
PISSN: 10553290
EISSN: None
Source Type: Journal
DOI: 10.1016/S1055-3290(06)60208-2 Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|